Pain is a significant clinical problem, and there is a need for pharmacotherapies that are more effective with fewer adverse effects than currently available medications. Cannabinoid receptor agonists enhance the antinociceptive effects of μ-opioid receptor agonists; it is unclear whether they impact the effects of agonists acting at other opioid receptors. κ-Opioid receptor agonists have antinociceptive effects, but their clinical use is precluded by adverse effects; however, their therapeutic potential might be realized if antinociceptive effects could be selectively enhanced. In this study, the antinociceptive effects of the cannabinoid receptor agonist CP55940 and the κ-opioid receptor agonist spiradoline, alone and in combination, were studied in rats (n = 7) using a warm water tail-withdrawal procedure. When administered alone, CP55940 (0.032-1.0 mg/kg) and spiradoline (1.0-32.0 mg/kg) increased tail-withdrawal latency, and mixtures of CP55940 and spiradoline (ratios of 1 : 3, 1 : 1, and 3 : 1) produced additive effects. It remains to be determined whether this additive interaction between a κ-opioid receptor agonist and a cannabinoid receptor agonist is selective for antinociception and whether it can be generalized to other drugs. Behavioural Pharmacology 27:69-72
Pain is a significant clinical problem, and there is a need for pharmacotherapies that are more effective with fewer adverse effects than currently available medications. Cannabinoid receptor agonists enhance the antinociceptive effects of μ-opioid receptor agonists; it is unclear whether they impact the effects of agonists acting at other opioid receptors. κ-Opioid receptor agonists have antinociceptive effects, but their clinical use is precluded by adverse effects; however, their therapeutic potential might be realized if antinociceptive effects could be selectively enhanced. In this study, the antinociceptive effects of the cannabinoid receptor agonist CP55940 and the κ-opioid receptor agonist spiradoline, alone and in combination, were studied in rats (n = 7) using a warm water tail-withdrawal procedure. When administered alone, CP55940 (0.032-1.0 mg/kg) and spiradoline (1.0-32.0 mg/kg) increased tail-withdrawal latency, and mixtures of CP55940 and spiradoline (ratios of 1 : 3, 1 : 1, and 3 : 1) produced additive effects. It remains to be determined whether this additive interaction between a κ-opioid receptor agonist and a cannabinoid receptor agonist is selective for antinociception and whether it can be generalized to other drugs. Behavioural Pharmacology 27:69-72 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Pain remains a significant clinical challenge (Gaskin and Richard, 2012) . μ-Opioid receptor agonists are commonly used to treat moderate to severe pain; however, their use is limited by unwanted effects (Benyamin et al., 2008) including overdose and abuse (Atluri et al., 2014) . There is a need for safer, more effective pharmacotherapies that have fewer adverse effects than currently available medications.
Often, drugs are used in combination to treat pain, allowing for the possibility that smaller doses can be combined to maintain or improve analgesic effectiveness while reducing or avoiding unwanted effects associated with larger doses of either drug alone (Gilron et al., 2013) . Cannabinoid receptor agonists (e.g. Δ 9 -tetrahydrocannabinol) have antinociceptive effects (Pertwee, 2001) , are used to treat pain (Hosking and Zajicek, 2008; Ware et al., 2010) , and enhance the antinociceptive effects of μ-opioid receptor agonists (Cichewicz, 2004; Li et al., 2008; Welch, 2009; Maguire et al., 2013; . It is unclear whether cannabinoid receptor agonists enhance the antinociceptive effects of other drugs, including agonists acting at other opioid receptors.
κ-Opioid receptor agonists such as spiradoline, a potent congener of U50488, have antinociceptive effects (VonVoigtlander and Lewis, 1988), but their use is precluded by adverse effects (Pfeiffer et al., 1986; Walsh et al., 2001) . However, their therapeutic potential might be realized if antinociceptive effects could be selectively enhanced, for example, by coadministration with another drug. κ-Opioid receptors appear to play a role in the antinociceptive effects of cannabinoids (Smith et al., 1994; Pugh et al., 1995 Pugh et al., , 1997 Reche et al., 1996; Mason et al., 1999) , suggesting that mixtures of cannabinoids and κ-opioids might be effective for treating pain. Few studies (e.g. Welch, 1993) have investigated interactions between the antinociceptive effects of cannabinoids and κ-opioids, and the nature of the interactions between these classes of drugs remains unclear.
This study examined the antinociceptive effects of spiradoline and the synthetic cannabinoid receptor agonist, CP55940, alone and in combination, in rats, using a warm water tail-withdrawal procedure. If cannabinoid receptor agonists enhance the antinociceptive effects of κ-opioid receptor agonists, mixtures of cannabinoids and κ-opioids might be useful for treating pain.
Methods

Subjects
Seven male Sprague-Dawley rats (Harlan Sprague-Dawley Inc., Indianapolis, Indiana, USA), ∼ 14 months old, were housed under conditions described previously . Water was available continuously in the home cage, and chow (15-20 g/day; Rat Sterilizable Diet; Harlan Teklad, Madison, Wisconsin) was provided after the session, maintaining the body weight at 420 15 g. The rats had previously received drugs (unpublished data), although not for at least 3 months before this study, and they had no experience with antinociception procedures. Tests were conducted no more than once weekly. The rats were cared for according to local Institutional Animal Care and Use Committe and National Institutes of Health guidelines.
Apparatus and procedure
Water baths (EW-14576-00; Cole-Parmer, Vernon Hills, Illinois, USA) maintained water at 40, 50, or 55°C. During the tests, ∼ 5 cm of the tail was immersed, and the time until the tail was withdrawn was recorded with a stopwatch. The test ended when the tail was completely removed or when the timer reached 20 s (maximum effect), whichever occurred first. Each temperature was tested once per cycle, with ∼ 30 s between tests; the order in which temperatures were tested varied across cycles. The rats were weighed, received a vehicle injection, and were returned to their home cages; 30 min later tail-withdrawal latencies were measured. Immediately after the first test, the rats received another injection and were returned to their home cages, followed 30 min later by another test. The sessions lasted until a 20-s latency was reached with 50°C or for six cycles, whichever occurred first.
Dose-effect curves were determined for spiradoline alone and then for CP55940 alone. The sessions began with a vehicle test, followed by tests with increasing cumulative doses (1/2 log unit) of spiradoline or CP55940 (Table 1) . Dose-effect curves were then determined for mixtures; the sessions began with a vehicle test, followed by increasing cumulative doses of spiradoline and CP55940. The ratio (1 : 1, 3 : 1, or 1 : 3) of CP55940 to spiradoline in the mixture remained constant for all cycles of a test session. The doses of the mixtures were determined from the doses that produced 50% of the maximum possible effect (ED 50 ) for the group mean dose-effect curves for CP55940 and spiradoline (50°C) alone.
Drugs
CP55940 [2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol; Sigma-Aldrich, St Louis, Missouri, USA] was dissolved in a 1 : 1 : 18 solution of absolute ethanol, Emulphor-620 (Rhone-Poulenc Inc., Princeton, New Jersey), and 0.9% sterile saline. When administered alone, spiradoline (U62066; Upjohn, Kalamazoo, Michigan, USA) was dissolved in 0.9% saline, and when administered in a mixture, it was dissolved in a 1 : 1 : 18 solution containing CP55940. Doses are expressed in terms of the salt; injections (1.0 ml/kg) were administered intraperitoneally.
Data analyses
Latencies were expressed as a percentage of the maximal possible effect (MPE), as follows: %MPE = [(test latency − control latency)/(20 s − control latency)] × 100. Control latencies were determined each session for individual subjects during the first test (after vehicle). Because latencies with 40°C were greater than 18 s (90% MPE) and latencies with 55°C rarely exceeded 7 s (35% MPE), results with these temperatures were not analyzed. A sigmoidal curve was fitted to the 50°C data for individual rats to determine the slope and ED 50 of the dose-effect curve, with the minimum and maximum constrained to 0 and 100%, respectively.
The interaction between CP55940 and spiradoline was examined as described by Tallarida (2000 Tallarida ( , 2006 . For each rat, the slope and ED 50 of the dose-effect curves were used to convert doses of CP55940 into spiradoline-equivalent doses. The spiradoline and spiradoline-equivalent doses (CP55490) in each mixture were summed to determine the additive total dose (in spiradoline-equivalent doses), which was used to determine the predicted effect. Predicted effects were averaged across rats and a straight line was fit to the group dose-effect curve using linear regression. Finally, the group dose-effect curve for predicted effects was compared with the group dose-effect curve for observed effects using an extra sum-of-squares F-test (Motulsky and Christopoulos, 2003) . Data for each ratio were analyzed separately. Curve fitting and statistical analyses were carried out using GraphPad Prism version 5.0 (San Diego, California, USA). 
Results
The mean tail-withdrawal latencies from 50°C water were 6.0 and 4.3 s following 1 : 1 : 18 vehicle and saline injections, respectively. Tail-withdrawal latency with 50°C water increased with increasing doses of CP55940 or spiradoline (open symbols, left and right panels of Fig. 1a) , with a group mean (95% confidence interval) ED 50 of 0.17 (0.08-0.34) mg/kg for CP55940 and 9.56 (3.96-23.07) mg/ kg for spiradoline. Mixtures of CP55940 and spiradoline dose-dependently increased tail-withdrawal latency (filled symbols, left and right panels of Fig. 1a) , with larger doses producing at least 75% MPE. Plotted on an isobologram (Fig. 1b) , the results indicate that the ED 50 for each dose ratio fell near the line of additivity and within the 95% confidence interval. The observed effects for each dose ratio (filled symbols, Fig. 1c) were not significantly different from the predicted effects [open symbols; F(2,66) = 1.03, NS for 1 : 3; F(2,52) = 0.29, NS for 1 : 1; and F(2,52) = 1.02, NS for 3 : 1].
Discussion
There is a need for pain treatments that are more effective and with fewer adverse effects than currently available drugs (e.g. oxycodone). κ-Opioid receptor agonists have antinociceptive effects, but their use is precluded by adverse effects (Pfeiffer et al., 1986) ; the therapeutic Mixtures of κ-opioid and cannabinoid Maguire and France 71 potential of κ-opioid receptor agonists might be realized if their antinociceptive effects could be enhanced. This study examined whether a cannabinoid receptor agonist enhances the antinociceptive effects of a κ-opioid receptor agonist.
Consistent with previous studies (Tseng and Craft, 2001; Terner et al. 2003) , CP55940 and spiradoline dosedependently increased tail-withdrawal latency when administered alone. Moreover, the observed effects of mixtures were not different from the predicted effects on the basis of dose-addition analysis. These data are consistent with a previous report showing that mixtures of selected doses of Δ 9 -tetrahydrocannabinol and the κ-opioid receptor agonist U50488 have antinociceptive effects in mice (Welch, 1993) . To the extent that smaller doses of κ-opioid receptor agonists (i.e. in a mixture) produce fewer and less severe adverse effects, these data suggest that mixtures might be useful for treating pain.
κ-Opioid receptor agonists have aversive effects in nonhuman (Mucha and Herz, 1985) and human (Pfeiffer et al., 1986) subjects, which limit their therapeutic use; cannabinoid receptor agonists can also have aversive effects (McGregor et al., 1996) and they are abused.
Mixtures of κ-opioid receptor agonists and cannabinoid receptor agonists would not be useful if the interactions between the adverse effects of these drugs were additive or greater than additive. However, the therapeutic utility (margin of safety) of the κ-opioid receptor agonist might be increased if cannabinoid receptor agonists attenuate the adverse effects of κ-opioid receptor agonists or if the interaction between these classes of drugs, for adverse effects, is less than additive (i.e. subadditive).
These results indicate that mixtures of the κ-opioid receptor agonist, spiradoline, and the cannabinoid receptor agonist, CP55940, produce additive effects in a warm water tail-withdrawal procedure in rats. It remains to be determined whether the nature of the interaction differs with mixtures of other drugs or with effects other than antinociception.
